A Note on COVID-19 and Alkahest Clinical Trials
At Alkahest, the well-being of our trial participants, sites, and employees remains our number one priority. Alkahest is monitoring the COVID-19 situation and developments and we are working on strategies to enable ongoing, safe participation in our clinical trials. We are following guidelines issued by the Centers for Disease Control and Prevention, the World Health Organization, and the regulatory agencies which provide oversight of our clinical trials. If you are a participant in one of our trials, please contact your clinical trial site if you have any questions or concerns. Thank you for your continued patience as we navigate these difficult times.
Alkahest is committed to guaranteeing the safety of the volunteers and patients who take part in our clinical trials. Clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and other regulatory bodies abroad and are required before a new therapy can be made publicly available to ensure safety and effectiveness. Clinical trials serve to determine whether a new therapeutic agent is beneficial for the treatment of a disease. Such a new therapeutic (drug) is not made available to patients outside of clinical trials until the FDA has reviewed data from clinical trials and approved the agent’s use for treatment. Patients who wish to enroll in a clinical trial need to contact a clinical trial site to determine whether they meet enrollment criteria.